Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.73 |
| ▸ | GLA | P06280 | 3/20 | 0.84 |
| ▸ | GAA | P10253 | 2/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.84 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.84 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.84 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.84 |
| ▸ | MMP1 | P03956 | 1/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL1408971 | 0.96 | GLA (0.78) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL28244782 | 0.96 | GLA (0.78) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL6464849 | 0.95 | GLA (0.75) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL12313065 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL13420262 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL19534323 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL29367581 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL4034 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL131381 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 | |
| Irinotecan SCHEMBL29356918 | 0.92 | GLA (1.00) | GLAGAASLC22A2CYP3A4SLC47A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058322-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230338520-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2023-10-26 | — | — | US | disclosed |
| US-11707518-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2023-07-25 | — | — | US | disclosed |
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-116209439-A | Substituted N- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) arylsulfonamide analogs as cereblon modulators | 圣裘德儿童研究医院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-03-01 | — | — | US | disclosed |
| US-20220008410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11045461-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040180946-A1 | Phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-09-16 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| US-20040116466-A1 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2004-06-17 | — | — | US | disclosed |
| WO-2004024897-A2 | PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024896-A2 | PHENYL-INDOLE COMPOUNDS | AVANIR PHARMACEUTICALS (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | CXCR4, CXCL12, CXCR1 | TOP1 3203/4885GLA 3058/4885GAA 2592/4885 |
| US-20040180946-A1 | Phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation | IDO1, IDO2, CMA1 | TOP1 2599/4885GLA 3794/4885GAA 3042/4885 |
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | TP53, HLA-DRB1, CD74 | TOP1 1455/4885GLA 2211/4885GAA 2213/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | TOP1 1213/4885GLA 2176/4885GAA 735/4885 |
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | TOP1 3203/4885GLA 3058/4885GAA 2592/4885 |
| US-20240058322-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | CXCR4, CXCL12, CXCR1 | TOP1 3203/4885GLA 3058/4885GAA 2592/4885 |
| US-11045461-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | TOP1 3203/4885GLA 3058/4885GAA 2592/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | TOP1 1864/4885GLA 3883/4885GAA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.